JP2019523295A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523295A5
JP2019523295A5 JP2019517209A JP2019517209A JP2019523295A5 JP 2019523295 A5 JP2019523295 A5 JP 2019523295A5 JP 2019517209 A JP2019517209 A JP 2019517209A JP 2019517209 A JP2019517209 A JP 2019517209A JP 2019523295 A5 JP2019523295 A5 JP 2019523295A5
Authority
JP
Japan
Prior art keywords
myostatin
pharmaceutical composition
smn
sma
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517209A
Other languages
English (en)
Japanese (ja)
Other versions
JP6823167B2 (ja
JP2019523295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/037332 external-priority patent/WO2017218592A1/en
Publication of JP2019523295A publication Critical patent/JP2019523295A/ja
Publication of JP2019523295A5 publication Critical patent/JP2019523295A5/ja
Application granted granted Critical
Publication of JP6823167B2 publication Critical patent/JP6823167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517209A 2016-06-13 2017-06-13 ミオスタチン阻害剤の使用および併用療法 Active JP6823167B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662349596P 2016-06-13 2016-06-13
US62/349,596 2016-06-13
US201762470157P 2017-03-10 2017-03-10
US62/470,157 2017-03-10
US201762486934P 2017-04-18 2017-04-18
US62/486,934 2017-04-18
US201762511702P 2017-05-26 2017-05-26
US62/511,702 2017-05-26
US201762512254P 2017-05-30 2017-05-30
US62/512,254 2017-05-30
PCT/US2017/037332 WO2017218592A1 (en) 2016-06-13 2017-06-13 Use of myostatin inhibitors and combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021000367A Division JP7161554B2 (ja) 2016-06-13 2021-01-05 ミオスタチン阻害剤の使用および併用療法

Publications (3)

Publication Number Publication Date
JP2019523295A JP2019523295A (ja) 2019-08-22
JP2019523295A5 true JP2019523295A5 (https=) 2020-07-16
JP6823167B2 JP6823167B2 (ja) 2021-01-27

Family

ID=59093642

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019517209A Active JP6823167B2 (ja) 2016-06-13 2017-06-13 ミオスタチン阻害剤の使用および併用療法
JP2021000367A Active JP7161554B2 (ja) 2016-06-13 2021-01-05 ミオスタチン阻害剤の使用および併用療法
JP2022064360A Active JP7344337B2 (ja) 2016-06-13 2022-04-08 ミオスタチン阻害剤の使用および併用療法
JP2023142275A Pending JP2023164920A (ja) 2016-06-13 2023-09-01 ミオスタチン阻害剤の使用および併用療法
JP2025136177A Pending JP2025183233A (ja) 2016-06-13 2025-08-19 ミオスタチン阻害剤の使用および併用療法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021000367A Active JP7161554B2 (ja) 2016-06-13 2021-01-05 ミオスタチン阻害剤の使用および併用療法
JP2022064360A Active JP7344337B2 (ja) 2016-06-13 2022-04-08 ミオスタチン阻害剤の使用および併用療法
JP2023142275A Pending JP2023164920A (ja) 2016-06-13 2023-09-01 ミオスタチン阻害剤の使用および併用療法
JP2025136177A Pending JP2025183233A (ja) 2016-06-13 2025-08-19 ミオスタチン阻害剤の使用および併用療法

Country Status (22)

Country Link
US (2) US10946036B2 (https=)
EP (3) EP3368069B1 (https=)
JP (5) JP6823167B2 (https=)
KR (5) KR20230028813A (https=)
AU (4) AU2017283546C1 (https=)
CL (1) CL2018003588A1 (https=)
CY (1) CY1123678T1 (https=)
DK (2) DK4218804T3 (https=)
ES (1) ES2830440T3 (https=)
FI (1) FI4218804T3 (https=)
HR (2) HRP20260160T1 (https=)
HU (1) HUE051480T2 (https=)
IL (3) IL301468A (https=)
LT (2) LT4218804T (https=)
MY (2) MY185614A (https=)
NZ (3) NZ789269A (https=)
PE (1) PE20190205A1 (https=)
PT (1) PT3368069T (https=)
RS (1) RS61090B1 (https=)
SI (2) SI3368069T1 (https=)
SM (1) SMT202000598T1 (https=)
WO (1) WO2017218592A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
KR102376582B1 (ko) * 2016-06-17 2022-03-18 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP4218817A3 (en) * 2017-01-06 2023-09-06 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018187209A1 (en) * 2017-04-03 2018-10-11 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2019170930A1 (es) * 2018-03-09 2019-09-12 Universitat De Lleida Tratamiento para la atrofia muscular espinal
WO2019204369A1 (en) * 2018-04-17 2019-10-24 Applied Stemcell, Inc. Compositions and methods for treating spinal muscular atrophy
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113993452A (zh) * 2019-06-19 2022-01-28 豪夫迈·罗氏有限公司 数字生物标志物
JP2022537266A (ja) * 2019-06-19 2022-08-25 エフ.ホフマン-ラ ロシュ アーゲー デジタルバイオマーカー
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
AU2021369471A1 (en) 2020-10-26 2023-06-15 Scholar Rock, Inc. Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
CA3221555A1 (en) 2021-06-23 2022-12-29 Kimberly LONG A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023057404A1 (en) * 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
DK4518970T3 (da) * 2022-05-04 2026-04-07 Scholar Rock Inc Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2026008041A1 (zh) * 2024-07-04 2026-01-08 江苏恒瑞医药股份有限公司 特异性结合潜伏肌生长抑制素的抗原结合分子及其医药用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
EP1574577A3 (en) 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
ES2288900T3 (es) 2001-10-05 2008-02-01 Affimed Therapeutics Ag Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
US8455627B2 (en) 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
MXPA05002968A (es) 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
EP1699820A2 (en) 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008500373A (ja) 2004-05-27 2008-01-10 アクセルロン ファーマ インコーポレーテッド ケルベロス(Cerberus)/ココ(Coco)誘導体およびそれらの使用
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007061995A2 (en) 2005-11-21 2007-05-31 Novartis Ag Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
EP2097095B1 (en) 2006-11-29 2016-01-27 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
EP2769731A1 (en) 2007-02-23 2014-08-27 The Trustees of Columbia University in the City of New York Methods to activate or block the HLA-E/QA-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
ATE542876T1 (de) 2007-03-30 2012-02-15 Merck Patent Gmbh Doppelbrechungsschicht mit negativer optischer dispersion
JP2010523684A (ja) 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法
WO2008150530A2 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JP5841845B2 (ja) 2009-02-24 2016-01-13 ソーク・インステチュート・フォー・バイオロジカル・スタディーズSalk Institute For Biological Studies TGF−βスーパーファミリーのデザイナーリガンド
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
US20130178454A1 (en) 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
JP2016500704A (ja) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドScholar Rock,Inc. 細胞シグナル伝達を変調するための組成物及び方法
MX380973B (es) * 2013-05-01 2025-03-12 Genzyme Corp Composiciones y metodos para tratar la atrofia muscular espinal.
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
US10004814B2 (en) 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015195094A1 (en) 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR20170135967A (ko) * 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Similar Documents

Publication Publication Date Title
JP2019523295A5 (https=)
HRP20201764T1 (hr) Upotreba inhibitora miostatina i kombinacijske terapije
JP7288927B2 (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのil-17アンタゴニストの使用
RU2017120437A (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
JP2011506483A5 (https=)
RU2014117510A (ru) Лечение ревматоидного артрита
RU2013155906A (ru) Антитела анти-angptl3 и их применение
JP2015503909A5 (https=)
JP2014525465A5 (https=)
JP2021193121A (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
JP2022126791A (ja) Il-17アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2018529661A5 (https=)
JP2020502261A5 (https=)
JP2022525164A5 (https=)
IL276896B2 (en) Methods of treating crohn's disease with anti-il23 specific antibody
JP2023138982A (ja) インターロイキン-17(il-17)アンタゴニストを使用して腱障害を治療する方法
JP2021532176A5 (https=)
JP2023537078A5 (https=)
JP2021523138A5 (https=)
JP2021523881A5 (https=)
TW202126329A (zh) 使用白細胞介素-17(il-17)拮抗劑治療自體免疫性疾病之方法
JP2024528877A5 (https=)
JP2021533142A5 (https=)
JP2023544620A5 (https=)